The safety of ramucirumab for the treatment of colorectal cancer

Alba Noguerido, Núria Mulet-Margalef, Ignacio Matos, Javier Ros, Guillem Argilés, Elena Élez, Josep Tabernero

Research output: Contribution to journalArticleResearch

6 Citations (Scopus)


© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Ramucirumab, a human monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2), is an antiangiogenic therapy that has been approved in combination with FOLFIRI in second-line treatment of metastatic colorectal cancer (mCRC), after progression on or after therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. A thorough review of the safety of ramucirumab in this setting and in the context of other antiangiogenic agents is merited. Areas covered: We provide an overview of activity and summarize in detail the overall safety and tolerability profile of ramucirumab in mCRC patients on the basis of a literature review of all published clinical trials in this setting, including both single-agent and combination studies. A focus on adverse events of interest and specific populations is included, as well as a critical comparison with other antiangiogenic therapies. Expert opinion: As an effective agent in pretreated mCRC patients, the toxicity profile of ramucirumab is similar to those of other angiogenesis inhibitors used in the second-line mCRC setting. The next challenge will be to find biomarkers of response and toxicity to antiangiogenic therapies in order to more effectively implement personalized medicine in these patients.
Original languageEnglish
Pages (from-to)945-951
JournalExpert Opinion on Drug Safety
Publication statusPublished - 2 Sep 2018


  • antiangiogenic antibodies
  • colorectal cancer
  • Ramucirumab
  • safety
  • side effects


Dive into the research topics of 'The safety of ramucirumab for the treatment of colorectal cancer'. Together they form a unique fingerprint.

Cite this